Skip to main content
PMC home page
Springer logoLink to Springer
. 2019 Mar 23;37(3):591. doi: 10.1007/s10637-019-00757-9

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Tetsuhide Ito 1,✉, Takuji Okusaka 2, Toshirou Nishida 3, Kenji Yamao 4, Hisato Igarashi 1, Chigusa Morizane 2, Shunsuke Kondo 2, Nobumasa Mizuno 4, Kazuo Hara 4, Akira Sawaki 4,5, Satoshi Hashigaki 6, Nobuyuki Kimura 6, Mami Murakami 6,7, Emiko Ohki 6, Richard C Chao 8, Masayuki Imamura 9
PMCID: PMC6828105  PMID: 30903344

Correction to: Invest New Drugs (2013) 31:1265–1274

10.1007/s10637-012-9910-y

In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s10637-012-9910-y

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Investigational New Drugs are provided here courtesy of Springer

RESOURCES